Opko Health Inc. (OPK)
OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue?
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y
OPK's Q1 earnings match estimates as pharma product sales rose, but revenue slides 25.7% after a smaller BioReference diagnostics base.
OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
OPKO Health (OPK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.
Here's Why You Should Hold OPK Stock in Your Portfolio for Now
OPKO Health rides on RAYALDEE strength, partnerships and restructuring gains, but reliance on a single drug keeps risk in focus for investors.
Here's Why You Should Hold OPK Stock in Your Portfolio for Now
OPK rides on RAYALDEE strength and partnerships, but revenue decline, losses, and reliance on a single drug cloud its near-term outlook.
Critical Analysis: OPKO Health (NASDAQ:OPK) vs. Hypertension Diagnostics (OTCMKTS:HDII)
OPKO Health (NASDAQ: OPK - Get Free Report) and Hypertension Diagnostics (OTCMKTS:HDII - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Earnings and Valuation This table compares OPKO Health
OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts
OPKO Health beats Q4 earnings and revenue estimates, but sales decline and gross margin narrows.
Compared to Estimates, OPKO Health (OPK) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.01 per share a year ago.
